why choose us

First received: March 02, 2023

Clinical Trial: CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma

Brief Summary: The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma.The names of the treatment interventions used in this study are:Cilta-cel (or chimeric antigen receptor T cells)Cyclophosphamide (a lymphodepleting chemotherapy)Fludarabine (a lymphodepleting chemotherapy)

Read more